Financhill
Sell
18

TERN Quote, Financials, Valuation and Earnings

Last price:
$3.18
Seasonality move :
-9.95%
Day range:
$3.16 - $3.50
52-week range:
$3.16 - $11.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.74x
Volume:
1.7M
Avg. volume:
1.2M
1-year change:
-52.68%
Market cap:
$269.7M
Revenue:
--
EPS (TTM):
-$1.18

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
TERN
Terns Pharmaceuticals
-- -$0.30 -- -7.38% $19.06
ALT
Altimmune
-- -$0.34 -88.8% -7.65% $22.38
AMGN
Amgen
$8.9B $5.08 8.14% 257.4% $315.95
LLY
Eli Lilly and
$13.4B $5.07 45.75% 89.16% $1,006.63
PFE
Pfizer
$17.3B $0.46 -3.03% 29.69% $31.32
VKTX
Viking Therapeutics
-- -$0.27 -- -21.87% $99.29
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
TERN
Terns Pharmaceuticals
$3.18 $19.06 $269.7M -- $0.00 0% --
ALT
Altimmune
$5.90 $22.38 $454.4M -- $0.00 0% 20,948.16x
AMGN
Amgen
$313.71 $315.95 $168.5B 41.55x $2.38 2.91% 5.07x
LLY
Eli Lilly and
$813.48 $1,006.63 $730.6B 69.47x $1.50 0.66% 16.33x
PFE
Pfizer
$25.72 $31.32 $145.8B 18.24x $0.43 6.57% 2.30x
VKTX
Viking Therapeutics
$30.89 $99.29 $3.5B -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
TERN
Terns Pharmaceuticals
-- 2.694 -- --
ALT
Altimmune
-- 3.397 -- 12.90x
AMGN
Amgen
91.09% 0.434 43.85% 0.84x
LLY
Eli Lilly and
70.33% 0.371 5.05% 0.59x
PFE
Pfizer
41.92% 0.618 43.87% 0.82x
VKTX
Viking Therapeutics
-- -1.225 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
TERN
Terns Pharmaceuticals
-- -$24.9M -- -- -- -$16.5M
ALT
Altimmune
-- -$24.9M -61.21% -61.21% -463580% -$18.3M
AMGN
Amgen
$6B $2.3B 5.97% 66.87% 16.83% $4.4B
LLY
Eli Lilly and
$11.1B $5.8B 25.09% 80.24% 38.89% $726.6M
PFE
Pfizer
$11.9B $3.2B 5.09% 8.91% 4.1% $5.8B
VKTX
Viking Therapeutics
-- -$46.2M -- -- -- -$31.2M

Terns Pharmaceuticals vs. Competitors

  • Which has Higher Returns TERN or ALT?

    Altimmune has a net margin of -- compared to Terns Pharmaceuticals's net margin of -463600%. Terns Pharmaceuticals's return on equity of -- beat Altimmune's return on equity of -61.21%.

    Company Gross Margin Earnings Per Share Invested Capital
    TERN
    Terns Pharmaceuticals
    -- -$0.28 --
    ALT
    Altimmune
    -- -$0.33 $123.5M
  • What do Analysts Say About TERN or ALT?

    Terns Pharmaceuticals has a consensus price target of $19.06, signalling upside risk potential of 500.39%. On the other hand Altimmune has an analysts' consensus of $22.38 which suggests that it could grow by 279.24%. Given that Terns Pharmaceuticals has higher upside potential than Altimmune, analysts believe Terns Pharmaceuticals is more attractive than Altimmune.

    Company Buy Ratings Hold Ratings Sell Ratings
    TERN
    Terns Pharmaceuticals
    5 3 0
    ALT
    Altimmune
    5 2 0
  • Is TERN or ALT More Risky?

    Terns Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Altimmune has a beta of 0.869, suggesting its less volatile than the S&P 500 by 13.083%.

  • Which is a Better Dividend Stock TERN or ALT?

    Terns Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Altimmune offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terns Pharmaceuticals pays -- of its earnings as a dividend. Altimmune pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TERN or ALT?

    Terns Pharmaceuticals quarterly revenues are --, which are smaller than Altimmune quarterly revenues of $5K. Terns Pharmaceuticals's net income of -$21.9M is higher than Altimmune's net income of -$23.2M. Notably, Terns Pharmaceuticals's price-to-earnings ratio is -- while Altimmune's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terns Pharmaceuticals is -- versus 20,948.16x for Altimmune. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TERN
    Terns Pharmaceuticals
    -- -- -- -$21.9M
    ALT
    Altimmune
    20,948.16x -- $5K -$23.2M
  • Which has Higher Returns TERN or AMGN?

    Amgen has a net margin of -- compared to Terns Pharmaceuticals's net margin of 6.9%. Terns Pharmaceuticals's return on equity of -- beat Amgen's return on equity of 66.87%.

    Company Gross Margin Earnings Per Share Invested Capital
    TERN
    Terns Pharmaceuticals
    -- -$0.28 --
    AMGN
    Amgen
    65.75% $1.16 $66B
  • What do Analysts Say About TERN or AMGN?

    Terns Pharmaceuticals has a consensus price target of $19.06, signalling upside risk potential of 500.39%. On the other hand Amgen has an analysts' consensus of $315.95 which suggests that it could grow by 0.71%. Given that Terns Pharmaceuticals has higher upside potential than Amgen, analysts believe Terns Pharmaceuticals is more attractive than Amgen.

    Company Buy Ratings Hold Ratings Sell Ratings
    TERN
    Terns Pharmaceuticals
    5 3 0
    AMGN
    Amgen
    9 14 2
  • Is TERN or AMGN More Risky?

    Terns Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amgen has a beta of 0.527, suggesting its less volatile than the S&P 500 by 47.288%.

  • Which is a Better Dividend Stock TERN or AMGN?

    Terns Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen offers a yield of 2.91% to investors and pays a quarterly dividend of $2.38 per share. Terns Pharmaceuticals pays -- of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend.

  • Which has Better Financial Ratios TERN or AMGN?

    Terns Pharmaceuticals quarterly revenues are --, which are smaller than Amgen quarterly revenues of $9.1B. Terns Pharmaceuticals's net income of -$21.9M is lower than Amgen's net income of $627M. Notably, Terns Pharmaceuticals's price-to-earnings ratio is -- while Amgen's PE ratio is 41.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terns Pharmaceuticals is -- versus 5.07x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TERN
    Terns Pharmaceuticals
    -- -- -- -$21.9M
    AMGN
    Amgen
    5.07x 41.55x $9.1B $627M
  • Which has Higher Returns TERN or LLY?

    Eli Lilly and has a net margin of -- compared to Terns Pharmaceuticals's net margin of 32.59%. Terns Pharmaceuticals's return on equity of -- beat Eli Lilly and's return on equity of 80.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    TERN
    Terns Pharmaceuticals
    -- -$0.28 --
    LLY
    Eli Lilly and
    82.24% $4.88 $47.9B
  • What do Analysts Say About TERN or LLY?

    Terns Pharmaceuticals has a consensus price target of $19.06, signalling upside risk potential of 500.39%. On the other hand Eli Lilly and has an analysts' consensus of $1,006.63 which suggests that it could grow by 23.74%. Given that Terns Pharmaceuticals has higher upside potential than Eli Lilly and, analysts believe Terns Pharmaceuticals is more attractive than Eli Lilly and.

    Company Buy Ratings Hold Ratings Sell Ratings
    TERN
    Terns Pharmaceuticals
    5 3 0
    LLY
    Eli Lilly and
    16 4 0
  • Is TERN or LLY More Risky?

    Terns Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.

  • Which is a Better Dividend Stock TERN or LLY?

    Terns Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.50 per share. Terns Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios TERN or LLY?

    Terns Pharmaceuticals quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Terns Pharmaceuticals's net income of -$21.9M is lower than Eli Lilly and's net income of $4.4B. Notably, Terns Pharmaceuticals's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 69.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terns Pharmaceuticals is -- versus 16.33x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TERN
    Terns Pharmaceuticals
    -- -- -- -$21.9M
    LLY
    Eli Lilly and
    16.33x 69.47x $13.5B $4.4B
  • Which has Higher Returns TERN or PFE?

    Pfizer has a net margin of -- compared to Terns Pharmaceuticals's net margin of 2.31%. Terns Pharmaceuticals's return on equity of -- beat Pfizer's return on equity of 8.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    TERN
    Terns Pharmaceuticals
    -- -$0.28 --
    PFE
    Pfizer
    66.74% $0.07 $152.1B
  • What do Analysts Say About TERN or PFE?

    Terns Pharmaceuticals has a consensus price target of $19.06, signalling upside risk potential of 500.39%. On the other hand Pfizer has an analysts' consensus of $31.32 which suggests that it could grow by 21.76%. Given that Terns Pharmaceuticals has higher upside potential than Pfizer, analysts believe Terns Pharmaceuticals is more attractive than Pfizer.

    Company Buy Ratings Hold Ratings Sell Ratings
    TERN
    Terns Pharmaceuticals
    5 3 0
    PFE
    Pfizer
    6 13 1
  • Is TERN or PFE More Risky?

    Terns Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer has a beta of 0.613, suggesting its less volatile than the S&P 500 by 38.72%.

  • Which is a Better Dividend Stock TERN or PFE?

    Terns Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.57% to investors and pays a quarterly dividend of $0.43 per share. Terns Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

  • Which has Better Financial Ratios TERN or PFE?

    Terns Pharmaceuticals quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $17.8B. Terns Pharmaceuticals's net income of -$21.9M is lower than Pfizer's net income of $410M. Notably, Terns Pharmaceuticals's price-to-earnings ratio is -- while Pfizer's PE ratio is 18.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terns Pharmaceuticals is -- versus 2.30x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TERN
    Terns Pharmaceuticals
    -- -- -- -$21.9M
    PFE
    Pfizer
    2.30x 18.24x $17.8B $410M
  • Which has Higher Returns TERN or VKTX?

    Viking Therapeutics has a net margin of -- compared to Terns Pharmaceuticals's net margin of --. Terns Pharmaceuticals's return on equity of -- beat Viking Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    TERN
    Terns Pharmaceuticals
    -- -$0.28 --
    VKTX
    Viking Therapeutics
    -- -$0.32 --
  • What do Analysts Say About TERN or VKTX?

    Terns Pharmaceuticals has a consensus price target of $19.06, signalling upside risk potential of 500.39%. On the other hand Viking Therapeutics has an analysts' consensus of $99.29 which suggests that it could grow by 221.44%. Given that Terns Pharmaceuticals has higher upside potential than Viking Therapeutics, analysts believe Terns Pharmaceuticals is more attractive than Viking Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    TERN
    Terns Pharmaceuticals
    5 3 0
    VKTX
    Viking Therapeutics
    9 1 0
  • Is TERN or VKTX More Risky?

    Terns Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.651%.

  • Which is a Better Dividend Stock TERN or VKTX?

    Terns Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Terns Pharmaceuticals pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios TERN or VKTX?

    Terns Pharmaceuticals quarterly revenues are --, which are smaller than Viking Therapeutics quarterly revenues of --. Terns Pharmaceuticals's net income of -$21.9M is higher than Viking Therapeutics's net income of -$35.4M. Notably, Terns Pharmaceuticals's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Terns Pharmaceuticals is -- versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    TERN
    Terns Pharmaceuticals
    -- -- -- -$21.9M
    VKTX
    Viking Therapeutics
    -- -- -- -$35.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Qualcomm Stock: 5G Leader at a Bargain Price?
Qualcomm Stock: 5G Leader at a Bargain Price?

Chip giant QUALCOMM Incorporated (NASDAQ:QCOM) was the ultimate chip company…

What Is Buffett Buying and Selling Now?
What Is Buffett Buying and Selling Now?

In Q4 of last year, Warren Buffett made a few…

3 Safest Stocks to Buy Now
3 Safest Stocks to Buy Now

With the S&P 500 now in correction and stocks selling…

Stock Ideas

Buy
52
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
59
GRRR alert for Mar 15

Gorilla Technology Group [GRRR] is up 29.72% over the past day.

Sell
49
SMTC alert for Mar 15

Semtech [SMTC] is up 21.28% over the past day.

Buy
62
PLPC alert for Mar 15

Preformed Line Products [PLPC] is up 17.38% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock